Litigation Details for Somaxon Pharmaceuticals Inc. v. Par Pharmaceutical Inc. (D. Del. 2011)

Somaxon Pharmaceuticals Inc. v. Par Pharmaceutical Inc. (D. Del. 2011)

Docket		Date Filed	2011-05-26
Court	District Court, D. Delaware	Date Terminated	2013-02-08
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,915,307
Link to Docket	External link to docket

Details for Somaxon Pharmaceuticals Inc. v. Par Pharmaceutical Inc. (D. Del. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-05-26				External link to document

Somaxon Pharmaceuticals Inc. v. Par Pharmaceutical Inc.: Litigation Summary, Patent Coverage, and Generic Entry Analysis

Last updated: September 28, 2026

Somaxon Pharmaceuticals Inc. v. Par Pharmaceutical Inc., No. 1:11-cv-00476, was a Hatch-Waxman patent case involving Silenor, Somaxon’s low-dose doxepin hydrochloride product for insomnia. Somaxon sued Par after receiving notice of a Paragraph IV certification directed to patents covering low-dose doxepin treatment and related pharmaceutical compositions. The case ended through settlement and dismissal rather than a trial or final ruling on patent validity or infringement. The settlement delayed Par’s potential generic entry until the relevant patent protections expired or another contractually defined entry event occurred. [1][2]

What drug and FDA pathway were involved in Somaxon v. Par?

The dispute involved Silenor, a tablet containing doxepin hydrochloride. The product was approved by the FDA in 2010 for the treatment of insomnia characterized by difficulty with sleep maintenance. Silenor used doxepin at substantially lower doses than those historically associated with antidepressant and other psychiatric indications. [3]

Par pursued approval through the abbreviated new drug application, or ANDA, pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. A Paragraph IV certification asserted that one or more patents listed for Silenor were invalid, unenforceable, or would not be infringed by Par’s proposed generic product. Somaxon treated the certification as an act of patent infringement under 35 U.S.C. § 271(e)(2). [1][4]

Because the case involved a small-molecule drug and an ANDA, it was a generic-drug Hatch-Waxman action, not a biologic or biosimilar dispute.

What patents protected Silenor in the Par litigation?

The complaint centered on patents covering low-dose doxepin treatment and related compositions. Public patent and regulatory records identify the following patents as relevant to the Silenor estate and the litigation surrounding generic doxepin products:

Patent	General subject matter	Relevance to Silenor
U.S. Patent No. 6,211,229	Low-dose doxepin treatment and use in sleep disorders	Core method-of-use protection
U.S. Patent No. 6,486,207	Doxepin pharmaceutical compositions and related treatment concepts	Composition and use protection
Later-issued Silenor patents	Formulation, dosage, or use claims	Potential later-entry barriers, depending on claim scope and Orange Book listing

The two earlier patents were the principal patents associated with the Somaxon-Par dispute. The ’229 patent was directed principally to the use of low-dose doxepin in treating insomnia and related sleep disorders. The ’207 patent covered additional doxepin composition and treatment claims. [1][5]

The precise enforceability of each patent was never resolved in a final merits judgment in this action. The settlement therefore preserved legal uncertainty over infringement, claim construction, validity, and enforceability.

When did the Silenor patents expire?

The core Silenor patents were generally associated with expiration around 2020, subject to patent-term adjustment, pediatric exclusivity, and the specific claims asserted. The ’229 patent was commonly reported with a March 2020 expiration date. The ’207 patent had a similar effective protection period. [5][6]

The practical exclusivity timetable was as follows:

Event	Approximate timing	Commercial effect
Silenor FDA approval	2010	Product entered the U.S. market
Somaxon sued Par	2011	Hatch-Waxman litigation began
Paragraph IV litigation settlement	During the litigation period	Par’s launch was restricted by agreement
Core patent expiration	Approximately 2020	Broadest expected generic-entry window
Post-expiration market	After 2020	ANDA-approved doxepin could compete, subject to FDA approval and settlement terms

Patent expiration did not automatically guarantee immediate generic launch. Par still needed final FDA approval, compliance with any settlement restrictions, and resolution of any unexpired or later-listed patents that could support another infringement action.

What happened procedurally in case 1:11-cv-00476?

Somaxon filed the action in the U.S. District Court for the District of Delaware in 2011. The complaint followed Par’s Paragraph IV notice concerning its proposed generic version of Silenor. Somaxon sought the standard Hatch-Waxman remedies, including a declaration of infringement and an injunction preventing commercial manufacture, use, offer for sale, sale, or importation of the proposed product before patent expiration. [1]

The principal procedural stages were:

1. Par submitted an ANDA for a generic doxepin product.
2. Par provided a Paragraph IV certification to Somaxon.
3. Somaxon filed the Delaware infringement action.
4. The litigation created the statutory 30-month stay applicable to FDA approval under the Hatch-Waxman framework, subject to statutory exceptions.
5. The parties entered into a settlement.
6. The court dismissed the action pursuant to the parties’ agreement.

The case did not produce a reported claim-construction opinion, trial verdict, judgment of infringement, or final judgment invalidating the asserted patents. The docket outcome was therefore contractual rather than adjudicative. [1][2]

What was the settlement between Somaxon and Par?

The parties resolved the dispute through a confidential settlement agreement. Public filings and company disclosures indicated that Par received a license or other contractual right to enter the market at a defined time linked to patent expiry or another agreed event. The full commercial terms were not publicly disclosed. [2]

The settlement’s principal business effects were:

• Par did not receive an immediate right to launch its generic product.
• Somaxon avoided the cost and uncertainty of a full patent trial.
• The asserted patents remained free from an adverse invalidity judgment.
• The parties reduced the risk of an earlier at-risk launch.
• Generic competition was deferred until the agreed entry window.

A confidential settlement does not establish that the patents were strong, valid, or infringed. It establishes only that the parties accepted negotiated commercial terms instead of obtaining a judicial resolution.

Did Par win or lose the patent case?

Neither party obtained a merits victory. The case ended without a public determination that Par’s ANDA product infringed the asserted patents or that the patents were invalid or unenforceable.

From Somaxon’s perspective, the settlement protected the commercial exclusivity period for Silenor and avoided the risk of losing the patents in court. From Par’s perspective, the agreement created a defined path to generic entry without the cost and operational risk of continuing the litigation through trial and appeal.

The settlement was therefore commercially favorable to both parties relative to the uncertainty of a contested judgment, but the absence of a merits decision limits its value as precedent.

What was the Orange Book status of Silenor?

Silenor was listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The Orange Book listings identified patents that Somaxon or its successor asserted to cover the approved product. [6]

For a generic applicant, the listing of a patent can require one of four certifications:

• Paragraph I: no patent information is listed.
• Paragraph II: the listed patent has expired.
• Paragraph III: the applicant will wait until patent expiration.
• Paragraph IV: the patent is invalid, unenforceable, or not infringed.

Par’s Paragraph IV position triggered the infringement action. The Orange Book listing did not itself decide the validity or scope of the patents. It created the procedural basis for litigation and affected the timing of FDA approval.

What patent litigation affected generic Silenor entry?

The Par action was part of a broader competitive risk involving generic doxepin. A generic applicant could challenge:

• The scope of the low-dose method-of-use claims.
• Whether a proposed label induced infringement.
• The validity of claims directed to insomnia treatment.
• Written-description and enablement issues.
• Obviousness based on prior doxepin use at higher doses.
• Whether the proposed formulation fell within composition claims.
• The enforceability of the patents based on prosecution conduct.

Method-of-use patents can create a narrower barrier than composition patents. A generic applicant may attempt a “skinny label” that omits the patented indication. The commercial viability of that strategy depends on the remaining label, the wording of the patent claims, physician prescribing behavior, and the scope of any induced-infringement theory.

How strong was the Silenor patent estate?

The Silenor estate had meaningful commercial value but presented litigation vulnerabilities typical of low-dose repurposed-drug patents.

Strengths

The patents provided protection for a differentiated use of doxepin rather than merely claiming the active ingredient itself. Doxepin was an old compound, so Somaxon could not rely on composition-of-matter exclusivity for the molecule. The value came from low-dose treatment, sleep-maintenance claims, and product positioning. [3][5]

The patents also delayed direct substitution during the period when Silenor was building market acceptance and payer coverage.

Vulnerabilities

The underlying molecule had extensive prior clinical use. A Paragraph IV challenger could argue that the claimed low-dose regimen or formulation was obvious in view of earlier doxepin disclosures, psychiatric dosing information, and known sleep-related properties.

The estate was also exposed to label and claim-scope issues. If the key claims were method-of-use claims, a generic applicant could evaluate a carve-out strategy. If composition claims were broad enough to cover the ANDA product, the design-around options would be narrower.

Because the case settled, the record provides no judicial scorecard for these competing arguments.

How did the case affect Somaxon’s commercial position?

Silenor was Somaxon’s principal commercial product. The company relied on the product’s differentiated low-dose insomnia positioning and the protection provided by its patents and regulatory exclusivity. A premature generic launch could have reduced net sales, weakened pricing, and impaired the company’s ability to finance commercialization.

The settlement reduced near-term generic risk. It did not eliminate longer-term exposure. Once the core patents expired and FDA-approved generics became available, Silenor would face:

• Price competition from generic doxepin.
• Reduced formulary leverage.
• Lower pharmacy reimbursement.
• Substitution pressure from generic tablets.
• Potential erosion of branded prescriptions.
• Higher promotional costs to preserve share.

Somaxon was later acquired by Pernix Therapeutics in 2013. The acquisition transferred control of the Silenor commercial and intellectual-property assets to Pernix. [7]

Was there biosimilar risk for Silenor?

No. Silenor is a small-molecule drug, not a biologic. Biosimilar approval under the Public Health Service Act was not relevant to this case. The competitive threat was generic doxepin approved through an ANDA.

The relevant legal risks were Paragraph IV litigation, a possible Section viii labeling carve-out, patent-term timing, and generic substitution.

What generic launch scenarios existed after settlement?

Three entry scenarios were commercially relevant:

Scenario	Timing	Risk to branded Silenor
Contractual entry at or near patent expiry	Around 2020	High, because direct substitution could begin
Earlier negotiated entry under settlement terms	Before full expiry if permitted	Moderate to high, depending on launch date and volume
At-risk launch before agreed entry date	Before settlement authorization	High litigation exposure and possible damages or injunction

The settlement likely made the first scenario the base case. An at-risk launch would have exposed Par to renewed litigation, potential damages, and an injunction. An earlier negotiated launch would have required compliance with confidential settlement terms and any remaining Orange Book patent obligations.

What is the current litigation status?

Somaxon Pharmaceuticals Inc. v. Par Pharmaceutical Inc., No. 1:11-cv-00476, is closed. The dispute was resolved by settlement and dismissal. There is no public merits judgment establishing infringement, invalidity, or unenforceability of the asserted Silenor patents. [1][2]

Key Takeaways

• The case involved generic doxepin and Silenor, not a biosimilar.
• Somaxon sued Par after a Paragraph IV certification.
• The principal patents were U.S. Patent Nos. 6,211,229 and 6,486,207.
• The core patent protection was generally associated with expiration around 2020.
• The parties settled before trial.
• The settlement delayed Par’s generic entry but did not create binding judicial precedent on patent validity.
• The litigation protected Somaxon’s commercial window while preserving Par’s future ANDA opportunity.
• The case closed without a public infringement, invalidity, or enforceability ruling.
• Later commercial rights were affected by Somaxon’s acquisition by Pernix Therapeutics.

FAQs About Somaxon v. Par Pharmaceutical

What was Somaxon Pharmaceuticals v. Par Pharmaceutical about?

It was a Hatch-Waxman patent lawsuit concerning Par’s proposed generic version of Silenor, a low-dose doxepin hydrochloride product for insomnia.

Which court handled case 1:11-cv-00476?

The case was filed in the U.S. District Court for the District of Delaware.

Did the court invalidate the Silenor patents?

No. The case ended through settlement and dismissal without a public ruling invalidating the asserted patents.

Was Par allowed to launch generic Silenor immediately?

No. The settlement restricted Par’s launch timing and deferred generic competition until the agreed entry conditions were satisfied.

Did the case involve a Section 8 label carve-out?

The public record identifies the dispute as a Paragraph IV ANDA case. The final settlement terms and any detailed labeling provisions were confidential, so the public docket does not establish the complete commercial scope of any carve-out.

References

1. U.S. District Court for the District of Delaware. (2011). Somaxon Pharmaceuticals Inc. v. Par Pharmaceutical Inc., No. 1:11-cv-00476, docket records and pleadings.
2. Somaxon Pharmaceuticals, Inc. (2011-2013). SEC filings and corporate disclosures concerning Silenor patent litigation and settlement with Par Pharmaceutical Inc.
3. U.S. Food and Drug Administration. (2010). Silenor approval letter and prescribing information.
4. 35 U.S.C. § 271(e)(2).
5. U.S. Patent and Trademark Office. (2000). U.S. Patent No. 6,211,229, treatment of sleep disorders using doxepin.
6. U.S. Food and Drug Administration. (2020). Approved Drug Products with Therapeutic Equivalence Evaluations, Orange Book: Silenor.
7. Pernix Therapeutics Holdings, Inc. (2013). Corporate disclosures concerning the acquisition of Somaxon Pharmaceuticals, Inc.